Rona Anhalt - Certara Chief Officer
| CERT Stock | USD 12.33 0.05 0.40% |
Executive
Rona Anhalt is Chief Officer of Certara
| Age | 60 |
| Address | 100 Overlook Center, Princeton, NJ, United States, 08540 |
| Phone | 609 716 7900 |
| Web | https://www.certara.com |
Rona Anhalt Latest Insider Activity
Tracking and analyzing the buying and selling activities of Rona Anhalt against Certara stock is an integral part of due diligence when investing in Certara. Rona Anhalt insider activity provides valuable insight into whether Certara is net buyers or sellers over its current business cycle. Note, Certara insiders must abide by specific rules, including filing SEC forms every time they buy or sell Certara'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Rona Anhalt over three months ago Acquisition by Rona Anhalt of 21440 shares of Certara subject to Rule 16b-3 |
Certara Management Efficiency
Return On Tangible Assets is likely to drop to -0.04 in 2025. Return On Capital Employed is likely to gain to -0.0012 in 2025. Non Current Liabilities Other is likely to gain to about 47.3 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 103.6 M in 2025. Certara's management efficiency ratios could be used to measure how well Certara manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brad Bennion | HealthEquity | N/A | |
| Tarah Bryan | Health Catalyst | N/A | |
| Linda Llewelyn | Health Catalyst | 57 | |
| Eric Beyer | Privia Health Group | N/A | |
| Scott Fenstermacher | HealthStream | 56 | |
| Sarath Degala | Privia Health Group | N/A | |
| Katie Cook | Evolent Health | N/A | |
| Jeffrey Selander | Health Catalyst | N/A | |
| Jay Stevens | Privia Health Group | N/A | |
| Robert Borchert | Privia Health Group | N/A | |
| Ryan Barry | Health Catalyst | N/A | |
| Jenny Harding | Privia Health Group | N/A | |
| Steve Lindsay | HealthEquity | N/A | |
| Megan Charko | National Research Corp | N/A | |
| Kevin Scharnhorst | Health Catalyst | N/A | |
| Maxine Liu | Health Catalyst | N/A | |
| Christophe Louvion | National Research Corp | 52 | |
| Emily Rafferty | Evolent Health | 41 | |
| Adam Brown | Health Catalyst | N/A | |
| Amanda Flanders | Health Catalyst | N/A | |
| Cheryl King | HealthEquity | N/A | |
Management Performance
| Return On Equity | -0.0295 | ||||
| Return On Asset | 0.0059 |
Certara Leadership Team
Elected by the shareholders, the Certara's board of directors comprises two types of representatives: Certara inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Certara. The board's role is to monitor Certara's management team and ensure that shareholders' interests are well served. Certara's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Certara's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Traynor, General VP | ||
| Frederic Bois, Head Advisor | ||
| Robert Aspbury, President Software | ||
| Sheila MBA, Chief Officer | ||
| Ron DiSantis, Senior Development | ||
| Patrick PharmD, President Solutions | ||
| David Mitchell, Senior Engagement | ||
| William Feehery, CEO Director | ||
| John III, Chief Officer | ||
| Max Kanevsky, Chief Officer | ||
| Andrew Schemick, Chief Officer | ||
| Rona Anhalt, Chief Officer | ||
| Nicolette Sherman, Chief Officer | ||
| Jaap Mandema, Chief Officer | ||
| Leif Pedersen, President Officer | ||
| Daniel Corcoran, Chief Counsel |
Certara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Certara a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0295 | ||||
| Return On Asset | 0.0059 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 2.06 B | ||||
| Shares Outstanding | 160.99 M | ||||
| Shares Owned By Insiders | 2.48 % | ||||
| Shares Owned By Institutions | 96.26 % | ||||
| Number Of Shares Shorted | 5.26 M | ||||
| Price To Book | 1.89 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Certara Stock Analysis
When running Certara's price analysis, check to measure Certara's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Certara is operating at the current time. Most of Certara's value examination focuses on studying past and present price action to predict the probability of Certara's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Certara's price. Additionally, you may evaluate how the addition of Certara to your portfolios can decrease your overall portfolio volatility.